TGFBR3 and nonpapillary renal cell carcinoma: Another study demonstrated that TGFBR3 has anticancer properties in ccRCC independent of TGF-β and its canonical mechanism of action, and that loss of this receptor may occur early during RCC carcinogenesis [143].